Results 101 to 110 of about 56,276 (247)

Recent progress on nanotechnologies for enhancing blood‐brain barrier permeability

Smart Molecules, EarlyView.
In this review, we summarize innovative strategies for harnessing the power of nanotechnology to enhance blood‐brain barrier permeability, a key challenge for central nervous system (CNS) drug delivery. We overview structural innovation of nanocarriers, improvements in targeting strategies, and nanotechnology‐enhanced brain imaging.
Qibin Liu, Zhuoqian Chen, Anthony Guiseppi‐Elie, Fanling Meng, Liang Luo   +4 more
wiley   +1 more source

Monoclonal antibodies. Basic features

Neurología (English Edition), 2011
Introduction: Monoclonal antibodies are a powerful tool in laboratory diagnosis and are increasingly used in the treatment of several diseases. Development: Antibody development and characterization has a long history and goes back to immunology itself ...
A. García Merino
doaj  

Exploring Morphology of Thermoplasmonic Nanoparticles to Synergize Immunotherapeutic Fibroblast Activation Protein‐Positive Cell Sensitization and Photothermal Therapy

Small Science, EarlyView.
Schematic of spherical and branched gold nanoparticle‐based nanocarriers conjugated with targeting modules (TMs), previously designed for chimeric antigen receptor T‐cell (CAR T‐cell) recognition of fibroblast activation protein (FAP). By combining immunotherapeutic TMs with thermoplasmonic AuNPs, these nanoconjugates selectively sensitize FAP ...
Ahmed Alsadig, Xuan Peng, Hugo Boutier, Liliana R. Loureiro, Anja Feldmann, René Hübner, Humberto Cabrera, Manja Kubeil, Michael Bachmann, Larysa Baraban   +9 more
wiley   +1 more source

Disease Clearance in Ulcerative Colitis: A Narrative Review

United European Gastroenterology Journal, EarlyView.
ABSTRACT Ulcerative colitis (UC) is a chronic relapsing disease with significant associated risks such as colectomy, hospitalization, or colorectal cancer. A treat‐to‐target approach that mitigates disease activity and progression from an early stage is needed.
Silvio Danese, Laurent Peyrin‐Biroulet, Vipul Jairath, Ferdinando D'Amico, Shashi Adsul, Christian Agboton, Fernando Magro   +6 more
wiley   +1 more source

The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC

VIEW, EarlyView.
Background The interaction between TIGIT and CD155 compromises immune cell efficacy in tumor targeting, potentially driving hepatocellular carcinoma (HCC) progression through diverse molecular pathways. What Was Done This study investigates the interplay between CD155 and TIGIT in regulating CD8+ T cell function and elucidates its implications in HCC ...
Wenting Li, Yukun Li, Yao Li, Mingqi Yang, Haichuan Peng, Hongwei Sun, Ping Jiang, Yizhun Zhu, Qiang Chen, Xiaobing Duan, Wei Zhao   +10 more
wiley   +1 more source

CT‐P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study

Allergy, EarlyView.
This study investigated the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria. Therapeutic equivalence between CT‐P39 and ref‑OMA (300 mg) was demonstrated by the primary endpoint – confidence intervals of the treatment difference in mean change ...
Sarbjit S. Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan   +16 more
wiley   +1 more source

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

Allergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy, Laura Vitale, Thomas O'Neill, Deena M. Maurer, Linda Malenchek, Andrea Crocker, Colleen Patterson, Laura Mills‐Chen, Virginia Saley, Nicole M. Antczak, James M. Boyer, Kelly M. McManus, Noe Rico Montanari, Russell A. Hammond, Joel Goldstein, Lawrence J. Thomas, Tibor Keler, Diego Alvarado   +17 more
wiley   +1 more source

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Pharmacogenomics and Personalized Medicine, 2014
Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech
Smolej L
doaj  

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

The progression of multiple myeloma is regulated by LILRB1 via the GATA2–SAGE1 pathway

British Journal of Haematology, EarlyView.
Summary Multiple myeloma (MM) is a haematological malignancy characterized by the clonal expansion of plasma cells within the bone marrow, thus resulting in the overproduction of monoclonal immunoglobulins. Despite the availability of various immunotherapeutic strategies, patient survival rates remain disappointingly low, thus underscoring the need for
Chiqi Chen, Xuanyi Zhou, Liyuan Cao, Wenqian Yang, Lietao Weng, Jin Yuan, Wen Zhou, Zhuo Yu, Junke Zheng   +8 more
wiley   +1 more source